Spencer Lindeman

Spencer Lindeman, Ph.D., currently serves as a Senior Research Scientist at Immunome, Inc. since October 2023, following the merger of MorphImmune and Immunome. Prior to this role, Spencer held positions as a Senior Scientist and Independent Consultant at MorphImmune, focusing on technical information transfer related to radioligand therapy from August 2021 to October 2023. Spencer's academic background includes a postdoctoral researcher role at Purdue University's Philip S. Low Lab, where research concentrated on ligand-targeted drugs for cancer and fibrosis from November 2015 to January 2023, along with previous positions as a laboratory technician and research assistant. Spencer earned a Ph.D. in Chemistry from Purdue University and a Bachelor's degree in Biochemistry from Brigham Young University.